Vai offline con l'app Player FM !
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors
Manage episode 447762949 series 1021077
Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024.
At the conference, Oncology Times reporter, Peter Goodwin, caught up with James Larkin, FRCP, PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.
185 episodi
Manage episode 447762949 series 1021077
Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024.
At the conference, Oncology Times reporter, Peter Goodwin, caught up with James Larkin, FRCP, PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.
185 episodi
Tüm bölümler
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.